1. Home
  2. BCYC vs ORGO Comparison

BCYC vs ORGO Comparison

Compare BCYC & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$4.66

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

HOLD

Current Price

$2.42

Market Cap

348.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCYC
ORGO
Founded
2009
1985
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.7M
348.6M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
BCYC
ORGO
Price
$4.66
$2.42
Analyst Decision
Buy
Strong Buy
Analyst Count
10
2
Target Price
$13.90
$8.50
AVG Volume (30 Days)
386.6K
1.3M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1600.00
EPS
N/A
N/A
Revenue
N/A
$564,169,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.04
52 Week Low
$4.24
$2.04
52 Week High
$9.36
$7.08

Technical Indicators

Market Signals
Indicator
BCYC
ORGO
Relative Strength Index (RSI) 42.25 47.52
Support Level $4.52 $2.26
Resistance Level $5.41 $2.63
Average True Range (ATR) 0.21 0.16
MACD -0.01 0.01
Stochastic Oscillator 20.14 56.52

Price Performance

Historical Comparison
BCYC
ORGO

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Share on Social Networks: